Inhibition of DPP-IV: A New Therapeutic Approach For The Treatment Of Type 2 Diabetes

Khushboo Kapadia, Gauresh Somani, Sadhana Sathaye


Drugs that inhibit dipeptidyl peptidase­4 (DPP­IV), a ubiquitous enzyme that rapidly inactivates both GLP­1 and GIP, increase active levels of these hormones and, in doing so, improve islet function and glycemic control in T2DM. DPP­IV inhibitors are a new class of anti-diabetic drugs that provide comparable efficacy to current treatments. Although they differ in terms of their chemistry, they are all small molecules which are orally available. They are effective as monotherapy in patients inadequately controlled with diet and exercise and as add­on therapy in combination with metformin, thiazolidinediones, and insulin. The DPP­IV inhibitors improve glycaemic control, reducing both fasting and postprandial glucose levels to lower HbA1c levels, without weight gain and with an apparently benign adverse event profile. Thus, the DPP­IV inhibitors are a promising new treatment option, especially for patients with early stage T2DM and more severe hyperglycemia.

Full Text:



King H, Aubert R E, Herman W H, ‘Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections’,Diabetes Care, 21, (9) (1998)1414-31.

Umpierrez G, Dagogo J S., ‘Role of thiazolidinediones in the management of type 2 diabetes: focus on ethnic minority populations’, Ethn Dis. (2006)16(1) 51-7

Hans-Ulrich Demutha, Christopher H.S. McIntosh, Raymond A. Pedersonb, ‘Type-2 diabetes—Therapy with dipeptidyl peptidase IV inhibitors’, BiochimicaetBiophysicaActa 1751 (2005) 33– 44.

Lambeir AM, Durinx C, Sharpe S et al., ‘Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV’Critical Reviews In Clinical Laboratory Sciences, 40, (2003)209–94.

Bo Ahren, ‘DPP-4 inhibitors’, Best Practice & Research Clinical Endocrinology & Metabolism 21, (4) (2007) 517–33.

C. F. Deacon, ‘Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review’, Diabetes, Obesity and Metabolism, 13(2011) 7–18.

Duez H, Cariou B, Staels B, ‘DPP-4 inhibitors in the treatment of type 2 diabetes’Biochem Pharmacol,83(7) ( 2012) 823-32

Holst JJ & Deacon CF. ‘Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type-2 Diabetes, Diabetes’, 47(11), (1998)1663–70.

Jing Wua, YidingChenb, Xiaoli Shia, Wei Gua, ‘Dipeptidyl peptidase IV(DPP IV): a novel emerging target for the treatment of type 2 diabetes’, Journal of Nanjing Medical University, 23, (4) (2009) 228–35

Deacon CF, ‘What do we know about the secretion and degradation of incretin hormones?’ RegulPept, 128(2), (2005)117-24.

R.E. Amori, J. Lau, A.G. Pittas, ‘Efficacy and safety of incretin therapy in type 2 diabetes systematic review and meta-analysis’, JAMA , 298 (2007) 194–206

Kyriakos K, ‘Incretin effect: GLP-1, GIP, DPP4,Diabetes Research And Clinical Practice, 93 (2011) S32–36.

Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF, Andersen DK, ‘The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects’,Regulatory Peptides, 14, 51(1) (1994) 63-74.

Thornberry NA, Gallwitz B, ‘Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)’,Best Pract Res ClinEndocrinolMetab, 23(4) (2009) 479-86.

Michael Cobble, DPP-4 Inhibitors: A New Therapeutic Class for the Treatment of Type 2 Diabetes, Journal of family practise,58, (10) (2009)

Anthony H. Barnett, ‘New treatments for type 2 diabetes in the UK – An evolving landscape’, primary care diabetes, 5 (2011) 1–7.

Roger Gadsby, ‘New treatments for type 2 diabetes—The DPP4 Inhibitors’, Primary care diabetes (2007) 209–11.

Carolyn F. Deacon, Jens J. Holst, ‘Dipeptidyl peptidase IV inhibitors: A promising new therapeutic approach for the management of type 2 diabetes’, The International Journal of Biochemistry & Cell Biology ,38 (2006) 831–44.

John Gerich, ‘DPP-4 inhibitors: What may be the clinical differentiators?’, Diabetes research and clinical practice ,90 (2010) 131–140

Shivanna Y, Koteshwara A, ‘Dipeptidyl Peptidase IV inhibitory activity of Mangiferaindica’, Journal of Natural Products, 3(2010)76-9

Rituparna C, Singh B et al, ‘Dipeptidyl Peptidase- IV Inhibitory Activity of Berberisaristata’, Journal of Natural Products, 4 (01) 2011; 158-163.

E.J. Verspohl, ‘Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors’, Pharmacology & Therapeutics, 124 (2009) 113–38.

Anne-Marie Lambeir, Simon Scharpe, Ingrid De Meester, ‘DPP4 inhibitors for diabetes—What next?’, Biochemical pharmacology, 7 (6) (2008) 1637–43.


  • There are currently no refbacks.